Heart Failure Treatments Such As Angiotensin Receptor/Neprilysin Inhibitor Improve Heart Failure Status and Glucose Metabolism

被引:2
作者
Kashiwagi, Yusuke [1 ]
Nagoshi, Tomohisa [1 ]
Ogawa, Kazuo [1 ]
Kawai, Makoto [1 ]
Yoshimura, Michihiro [1 ]
机构
[1] Jikei Univ, Sch Med, Dept Internal Med, Div Cardiol, Tokyo, Japan
关键词
glucose metabolism; islet beta-cell function; insulin resistance; heart failure with reduced ejection fraction; angiotensin receptor; neprilysin inhibitor; CONVERTING ENZYME-INHIBITORS; TYPE-2; DIABETES-MELLITUS; INSULIN-RESISTANCE; ENALAPRIL; METAANALYSIS; GLYCEMIA; SYSTEM;
D O I
10.7759/cureus.22762
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A recent study suggested that angiotensin receptor/neprilysin inhibitor (ARNI; sacubitril/valsartan) can improve functional capacity and cardiac reverse remodeling in patients with heart failure with reduced ejection fraction (HFrEF). Another study suggested that ARNI reduced glycated hemoglobin (HbA1c) in patients with diabetes and HFrEF; however, the details of its efficacy are unknown. We herein report a case of HFrEF with abnormal glucose metabolism in which ARNI was initiated. On the 7th day of admission (before the initiation of ARNI), blood tests showed an abnormal glucose metabolism as follows: fasting blood glucose 134 mg/dL; and fasting blood insulin 11.4 mu U/mL (homeostasis model assessment of insulin resistance (HOMA-IR) index 3.77; homeostasis model assessment of 13-cell function (HOMA-13), 57.8%). On the 23rd day after the initiation of ARNI, even though the patient was not using hypoglycemic drugs, his fasting blood glucose markedly decreased to 70 mg/dL without hypoglycemic symptoms, and his fasting blood insulin decreased to 5.4 mu U/mL (HOMA-IR decreased to 0.93, HOMA-13 increased to 277.7%). These results imply that ARNI has the potential to improve insulin resistance and the islet beta-cell function in patients with heart failure, in addition to the original effect of improving the hemodynamics, although the effect of improving the glucose metabolism is also considered to have been influenced by the improvement of the heart failure status and other drugs that the patient was taking.
引用
收藏
页数:5
相关论文
共 50 条
  • [11] Frailty and uptake of angiotensin receptor neprilysin inhibitor for heart failure with reduced ejection fraction
    Lee, Yu-Chien
    Lin, Joshua K.
    Ko, Darae
    Cheng, Susan
    Patorno, Elisabetta
    Glynn, Robert J.
    Tsacogianis, Theodore
    Kim, Dae Hyun
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2023, 71 (10) : 3110 - 3121
  • [12] Angiotensin receptor blocker-neprilysin inhibitor for heart failure with reduced ejection fraction
    Nasrallah, Dima
    Abdelhamid, Alaa
    Tluli, Omar
    Al-Haneedi, Yaman
    Dakik, Habib
    Eid, Ali H.
    PHARMACOLOGICAL RESEARCH, 2024, 204
  • [13] Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure
    Prenner, Stuart B.
    Shah, Sanjiv J.
    Yancy, Clyde W.
    CURRENT ATHEROSCLEROSIS REPORTS, 2016, 18 (08)
  • [14] Angiotensin receptor neprilysin inhibitors in older patients with heart failure
    Sharkey, Anthony T.
    Ghafar, Mohd Zaquan
    O'Keeffe, Shaun T.
    Mulkerrin, Eamon C.
    BMJ EVIDENCE-BASED MEDICINE, 2019, 24 (01) : 5 - 7
  • [15] Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure
    Fonarow, Gregg C.
    Hernandez, Adrian F.
    Solomon, Scott D.
    Yancy, Clyde W.
    JAMA CARDIOLOGY, 2016, 1 (06) : 714 - 717
  • [16] Angiotensin receptor neprilysin inhibitor in chronic heart failure and comorbidity management: Indian consensus statement
    Mittal, Sanjay
    Harikrishnan, Sivadasanpillai
    Gupta, Anoop
    Bansal, Sandeep
    Koshy, George A.
    Mohanan, Padhinhare P.
    Bhattacharya, Debdatta
    Kerkar, Prafulla
    Swamy, Ajay
    Aggarwal, Vinayak
    Srivastava, Sameer
    Mahajan, Ajay
    Mehta, Ashwani
    Sharma, Kamal
    Shetty, Sadanand
    THERAPEUTIC ADVANCES IN CARDIOVASCULAR DISEASE, 2024, 18
  • [17] The Management Outcome of Heart Failure Reduced Ejection Fraction with or without Angiotensin Receptor Neprilysin Inhibitor
    Teng, W. J.
    Suliman, A. S. Ali
    Wyh, W. Isa
    IIUM MEDICAL JOURNAL MALAYSIA, 2024, 23 (04): : 38 - 44
  • [18] Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction
    Docherty, Kieran F.
    McMurray, John J. V.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2019, 281 : 179 - 185
  • [19] Benefits of Angiotensin Receptor-Neprilysin Inhibitor in Heart Failure with Reduced Ejection Fraction: A Longitudinal Study
    Jain, Dharmendra
    Pandey, Umesh Kumar
    Tripathi, Suyash
    Kaushley, Abhishek
    Verma, Bhupendra
    Ghosh, Soumik
    Santosh, Krishna Vemuri
    Prajapati, Rajpal
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2022, 16 (04) : EC17 - EC22
  • [20] Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings
    Ksiazczyk, Marcin
    Lelonek, Malgorzata
    HEART FAILURE REVIEWS, 2020, 25 (03) : 393 - 402